Trial Profile
A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms UNICAB
- 27 Jan 2024 Results assessing cabozantinib in locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or in those unsuitable for immunotherapy presented at the 2024 Genitourinary Cancers Symposium.
- 14 Feb 2022 Planned primary completion date changed from 30 Apr 2022 to 30 Oct 2022.
- 10 Apr 2019 Status changed from not yet recruiting to recruiting.